Short answer
Approximate detection windows.
These windows apply best to sublingual or buccal buprenorphine products such as Suboxone, Zubsolv, generic buprenorphine/naloxone, and generic buprenorphine tablets. “Subutex” is often used informally to mean buprenorphine-only tablets, but the original Subutex brand is no longer marketed in the United States. Generic buprenorphine-only sublingual tablets remain available.
Pharmacokinetics
Buprenorphine pharmacokinetics.
Per Suboxone prescribing information and pharmacokinetic references:
- Time to peak plasma concentration: roughly 30 minutes to 3.5 hours after sublingual or buccal dosing, depending on product and dose.
- Mean terminal half-life: approximately 24 to 42 hours for buprenorphine after Suboxone film.
- Main metabolite: norbuprenorphine.
- Metabolism: primarily hepatic, including CYP3A4-mediated N-dealkylation and glucuronidation.
- Excretion: mostly fecal, with a smaller urinary component.
Buprenorphine’s long half-life is one reason it can usually be dosed once daily for opioid use disorder. It is also why withdrawal after stopping tends to start later than withdrawal from short-acting opioids.
What gets tested
What buprenorphine tests detect.
Buprenorphine-specific drug tests may look for:
- Buprenorphine, the parent drug.
- Norbuprenorphine, the main metabolite.
- Buprenorphine-glucuronide and norbuprenorphine-glucuronide, depending on the laboratory.
In clinical care, norbuprenorphine is useful because it supports that buprenorphine was metabolized after ingestion. Very high buprenorphine with very low or absent norbuprenorphine can raise concern for possible urine spiking, although interpretation depends on timing, dose, formulation, urine concentration, and the lab method.
A positive urine test generally indicates recent exposure, not the exact dose taken. Quantitative urine levels should not be used as a simple “dose meter.” They are best interpreted as patterns over time.
Standard drug screens
Standard drug tests do not reliably detect buprenorphine.
Standard opiate immunoassays usually target morphine and codeine-type compounds. They do not reliably detect buprenorphine. Buprenorphine usually needs to be ordered specifically, either as a buprenorphine screen or as confirmatory testing by LC-MS/MS.
This matters because a “negative opioid screen” does not prove the patient is not taking buprenorphine. It may only mean the panel did not include buprenorphine.
Buprenorphine-specific testing is commonly added in:
- Addiction treatment programs.
- Drug courts and probation programs.
- Some pain clinics.
- Safety-sensitive employment testing when the policy includes it.
- Clinical situations where adherence, diversion, or unexpected results need clarification.
What affects detection
Factors that affect detection time.
Detection windows vary by individual based on:
- Dose.
- Duration and frequency of use.
- Time since last dose.
- Sublingual or buccal technique.
- Liver function.
- Co-administered CYP3A4 inhibitors or inducers.
- Urine concentration and hydration status.
- Assay cutoff and testing method.
- Formulation: sublingual, buccal, transdermal, implant, weekly injection, or monthly injection.
Extended-release
Sublocade and Brixadi: extended-release buprenorphine.
Sublocade and Brixadi are not the same as sublingual Suboxone or buprenorphine tablets. They are extended-release injectable formulations that release buprenorphine slowly over time.
Sublocade: After steady state has been achieved, generally after 4 to 6 months, product labeling states that patients may have detectable plasma and urine levels of buprenorphine for 12 months or longer after stopping.
Brixadi: Weekly and monthly formulations have different pharmacokinetic profiles. Detection can last substantially longer than after a single sublingual dose, especially with monthly dosing, but the exact window depends on dose, duration, and assay.
If you are on an extended-release injectable product, do not use a standard Suboxone detection table. Ask the prescribing clinician or laboratory for interpretation.
If you have a drug test
What to do if you have a drug test scheduled.
If you are taking buprenorphine as prescribed:
- Keep documentation of your prescription.
- Ask whether the test includes buprenorphine.
- For employment testing, ask about the medical review officer process rather than disclosing detailed medical information unnecessarily.
- If the result could affect court, probation, custody, housing, or employment, ask your prescriber whether a concise treatment-verification letter is appropriate.
Medical note
Buprenorphine should not be stopped abruptly without clinical guidance. Withdrawal can be uncomfortable, and discontinuation can increase overdose risk if a person returns to illicit opioid use after tolerance has fallen. This page is educational and does not replace medical care.